Hofgaard PO - Search Results

1

Primary antitumor immune response mediated by CD4+ T cells.

Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Corthay A, et al. Among authors: hofgaard po. Immunity. 2005 Mar;22(3):371-83. doi: 10.1016/j.immuni.2005.02.003. Immunity. 2005. PMID: 15780993 Free article.

2

Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.

Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF. Bogen B, et al. Eur J Immunol. 1995 Nov;25(11):3079-86. doi: 10.1002/eji.1830251114. Eur J Immunol. 1995. PMID: 7489746

3

Clonal deletion of thymocytes as a tumor escape mechanism.

Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B. Lauritzsen GF, et al. Among authors: hofgaard po. Int J Cancer. 1998 Oct 5;78(2):216-22. doi: 10.1002/(sici)1097-0215(19981005)78:2<216::aid-ijc16>3.0.co;2-8. Int J Cancer. 1998. PMID: 9754655

4

Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies.

Lundin KU, Hofgaard PO, Omholt H, Munthe LA, Corthay A, Bogen B. Lundin KU, et al. Among authors: hofgaard po. Blood. 2003 Jul 15;102(2):605-12. doi: 10.1182/blood-2002-11-3381. Epub 2003 Mar 20. Blood. 2003. PMID: 12649166 Free article.

5

Liver metastasis of cancer facilitated by chemokine receptor CCR6.

Dellacasagrande J, Schreurs OJ, Hofgaard PO, Omholt H, Steinsvoll S, Schenck K, Bogen B, Dembic Z. Dellacasagrande J, et al. Among authors: hofgaard po. Scand J Immunol. 2003 Jun;57(6):534-44. doi: 10.1046/j.1365-3083.2003.01263.x. Scand J Immunol. 2003. PMID: 12791091 Free article.

6

Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.

Dembic Z, Hofgaard PO, Omholt H, Bogen B. Dembic Z, et al. Among authors: hofgaard po. Scand J Immunol. 2004 Jul-Aug;60(1-2):143-52. doi: 10.1111/j.0300-9475.2004.01435.x. Scand J Immunol. 2004. PMID: 15238083 Free article.

7

CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo.

Lundin KU, Screpanti V, Omholt H, Hofgaard PO, Yagita H, Grandien A, Bogen B. Lundin KU, et al. Among authors: hofgaard po. Cancer Immunol Immunother. 2004 Dec;53(12):1135-45. doi: 10.1007/s00262-004-0538-4. Cancer Immunol Immunother. 2004. PMID: 15696611 Free PMC article.

8

Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.

Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B. Corthay A, et al. Among authors: hofgaard po. Cancer Res. 2009 Jul 15;69(14):5901-7. doi: 10.1158/0008-5472.CAN-08-4816. Epub 2009 Jun 30. Cancer Res. 2009. PMID: 19567679

9

Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model.

Follin-Arbelet V, Hofgaard PO, Hauglin H, Naderi S, Sundan A, Blomhoff R, Bogen B, Blomhoff HK. Follin-Arbelet V, et al. Among authors: hofgaard po. BMC Cancer. 2011 Jul 18;11:301. doi: 10.1186/1471-2407-11-301. BMC Cancer. 2011. PMID: 21767374 Free PMC article.

10

A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.

Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H, Schwarzer R, Schünemann N, Jundt F, Lindeberg MM, Bogen B. Hofgaard PO, et al. PLoS One. 2012;7(12):e51892. doi: 10.1371/journal.pone.0051892. Epub 2012 Dec 20. PLoS One. 2012. PMID: 23284805 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters